Medical Oncologist
Mutation & targeted therapy
PALB2, ATM and BRCA-Like Mutations: — Which PARP Inhibitors Apply?
PALB2, ATM and related gene mutations affect the same DNA-repair pathway as BRCA1 and BRCA2, and PARP inhibitors — the drug class that changed outcomes in BRCA cancers — now have regulatory approval or substantial evidence for several of them. Which ones apply to you depends on the specific gene, the cancer type, and whether the mutation is inherited or arose only in the tumour.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- Same pathway, different evidence — PALB2, ATM, RAD51C and RAD51D all disrupt the same homologous recombination repair process as BRCA, but the strength of evidence for PARP inhibitors differs by gene.
- PALB2 has the strongest case — After BRCA1 and BRCA2, PALB2 has the most established evidence for PARP inhibitors in breast cancer, with a regulatory approval now in place.
- ATM is more complex — ATM works differently from BRCA, and the evidence for PARP inhibitors is less consistent — the response varies by cancer type and mutation type.
- Germline vs somatic changes the answer — Most approvals apply to inherited mutations present in every cell. A mutation found only in tumour tissue may not meet the same criteria.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
PALB2, ATM, RAD51C, RAD51D and related mutations affect the same DNA-repair pathway as BRCA1 and BRCA2. PARP inhibitors — the drug class approved for BRCA cancers — now have regulatory approval or strong clinical evidence for several of these genes. The strength of that evidence differs by gene and cancer type; your oncologist will confirm which applies to you.
What do these gene names mean?
- PALB2
- Partner and Localizer of BRCA2. This gene helps BRCA2 reach damaged DNA and carry out repairs. A PALB2 mutation causes the same type of homologous recombination failure as a BRCA2 mutation, which is why the same drug class can apply.
- ATM
- Ataxia Telangiectasia Mutated. ATM acts as a sensor and alarm for DNA damage — it detects breaks and signals repair machinery to respond. Mutations in ATM impair this signalling, but differently from BRCA mutations, which is why the evidence for PARP inhibitors is less straightforward.
- Homologous recombination deficiency (HRD)
- The term for the DNA-repair failure that BRCA1, BRCA2, PALB2, RAD51C and RAD51D mutations all cause. Cells with HRD cannot fix certain double-strand DNA breaks accurately, which makes them vulnerable to a specific targeted drug class.
- PARP inhibitors
- A class of targeted drugs — including olaparib, niraparib, talazoparib and rucaparib — that block a backup DNA-repair pathway. When the BRCA-pathway is already broken by mutation, blocking PARP causes cancer cells to accumulate fatal DNA damage and die. This is called synthetic lethality.
- Germline vs somatic mutation
- A germline mutation is inherited and present in every cell of the body. A somatic mutation arose in the tumour only. Most current PARP inhibitor approvals specify germline mutations, though some indications now also cover somatic findings — ask your oncologist which type your result is.
Does a PALB2 mutation qualify you for PARP inhibitors?
For breast cancer, yes. Olaparib received regulatory approval for germline PALB2-mutated HER2-negative metastatic breast cancer, based on evidence that responses in PALB2-mutated tumours are comparable to those seen in BRCA1 and BRCA2-mutated tumours.
For pancreatic and ovarian cancer, evidence is accumulating but approvals are less established than for BRCA. Your oncologist may consider a PARP inhibitor under expanded indications or within a clinical trial.
If your report names PALB2, confirm with your oncologist whether the finding is germline, and ask which current approvals apply to your specific cancer type and stage.
Does an ATM mutation qualify for the same treatment as BRCA?
Not reliably. ATM mutations produce a different kind of repair impairment from BRCA mutations, and clinical trials have found less consistent responses to PARP inhibitors across cancer types.
In prostate cancer, the PROfound trial included patients with ATM mutations alongside BRCA mutations, but the signal in the ATM subgroup was weaker. NCCN guidelines for prostate cancer note ATM as a relevant mutation but distinguish its evidence level from BRCA1 and BRCA2.
Do not assume that an ATM result gives you the same drug options as a BRCA result. Ask your oncologist directly what an ATM finding means for your specific cancer type, and whether the mutation is germline or somatic — both affect which options are available.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What about RAD51C, RAD51D, CHEK2 and other genes on your panel?
RAD51C and RAD51D mutations cause the same type of HRD as BRCA mutations. In ovarian cancer, both are recognised as HRD genes in ESMO and NCCN guidance, and clinical evidence supports PARP inhibitor activity in this setting.
CHEK2 is a checkpoint gene downstream of ATM. The evidence for PARP inhibitors in CHEK2-mutated cancers is more limited, and CHEK2 is not currently listed as a qualifying mutation for most approved PARP inhibitor indications.
Multigene panels often return results for ten to twenty genes. Not every finding carries the same treatment implications now. Your oncologist or a clinical geneticist can explain which results are actionable today and which are worth monitoring as evidence matures.
Questions to ask at your next appointment
- Is my mutation germline or somatic, and does that change which drugs apply?
- Which specific PARP inhibitor, if any, has approval for my gene and cancer type?
- Should I have HRD testing on tumour tissue in addition to my germline result?
- Is there a clinical trial testing a PARP inhibitor or other targeted drug for my mutation?
- Do any other results on my panel have treatment implications now?
- Should my first-degree relatives be informed so they can consider genetic testing?
Which PARP inhibitor applies to which gene and cancer type?
PALB2 — breast cancer
Olaparib has regulatory approval for germline PALB2-mutated HER2-negative metastatic breast cancer, based on evidence that response rates are comparable to those seen with BRCA mutations. Talazoparib is approved for germline BRCA1/2-mutated breast cancer and is being studied in PALB2-mutated disease. Your oncologist will confirm which agent is appropriate for your specific situation and line of treatment, and whether the approval in India currently covers PALB2 alongside BRCA.
PALB2 — pancreatic and ovarian cancer
Evidence for PARP inhibitors in PALB2-mutated pancreatic cancer is emerging from clinical trials, but approvals are less established than for BRCA2-mutated pancreatic cancer. In ovarian cancer, PALB2 is recognised in HRD guidance, but the evidence base is still developing. Clinical trial enrolment is the strongest available route in both settings if standard approvals do not yet cover your mutation.
ATM — prostate cancer
The PROfound trial studied olaparib in men with castration-resistant prostate cancer carrying HRD gene mutations, including ATM. A response signal was present in the ATM group, but it was weaker than in BRCA1/2-mutated patients. NCCN guidance for prostate cancer notes this distinction. Olaparib carries approval in certain prostate cancer settings involving HRD mutations, but your oncologist needs to confirm whether ATM alone qualifies under the current approved label and CDSCO-recognised indications in India.
ATM — breast and other cancers
In breast cancer, germline ATM mutations increase risk, but the evidence for treating ATM-mutated breast cancer with PARP inhibitors is not established to the same standard as for BRCA or PALB2. Current ASCO and NCCN guidance does not list ATM as a qualifying mutation for PARP inhibitor approval in breast cancer. Clinical trials are the appropriate route if PARP inhibitor access is being considered for an ATM-mutated breast cancer in a setting where no standard approval applies.
RAD51C and RAD51D — ovarian cancer
RAD51C and RAD51D are recognised HRD genes in ESMO and NCCN ovarian cancer guidelines. Niraparib and rucaparib have demonstrated activity in RAD51-mutated ovarian cancer in clinical data. Depending on the line of treatment and local approval status, these mutations may qualify for PARP inhibitor therapy. Your oncologist should verify the current regulatory status in India, as approvals for non-BRCA HRD mutations continue to evolve.
CHEK2, NBN, BARD1 and other panel results
These genes sometimes appear on multigene cancer panels. For most, the evidence for PARP inhibitors or other targeted drugs is either in early clinical trial stages or not yet established in a way that changes standard treatment. A positive result for these genes is important for risk assessment and family counselling, and may become actionable as trial data matures — but it does not currently carry the same immediate treatment implications as BRCA1, BRCA2, PALB2 or the RAD51 genes.
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Is a PALB2 mutation as serious as a BRCA mutation?
PALB2 mutations carry a meaningful increase in cancer risk, particularly for breast cancer, and in terms of treatment options, PALB2 now has regulatory approval for PARP inhibitors in some settings — which was previously only true of BRCA1 and BRCA2. For risk, population studies suggest PALB2 generally sits between CHEK2 and BRCA2 in terms of magnitude. For treatment eligibility, the gap between PALB2 and BRCA has narrowed. Ask your oncologist and a genetic counsellor to interpret your specific result in the context of your personal and family history rather than comparing labels.
My report says I have an ATM mutation. Will I get a PARP inhibitor?
Not automatically. ATM mutations do not confer the same straightforward PARP inhibitor eligibility as BRCA1 or BRCA2. Whether you qualify depends on your cancer type, the current approved indications, and whether your oncologist considers the available evidence sufficient for your specific situation. In prostate cancer, there is the clearest — if limited — evidence. In other cancer types the picture is less settled. Ask your oncologist what ATM means for your treatment plan rather than assuming it does or does not qualify you.
My test was done on tumour tissue, not blood. Does that change anything?
Yes, it can. Most current PARP inhibitor approvals specify germline mutations — inherited mutations present in every cell. A mutation found only in tumour tissue is called somatic, and the treatment implications may differ. Somatic BRCA mutations are increasingly recognised in drug approvals for some cancer types, but this does not automatically extend to somatic PALB2 or ATM findings. Ask your oncologist whether your result is germline, somatic, or whether a blood test is still needed to clarify — and what the answer means for your eligibility.
What is the difference between HRD testing and a gene panel test?
A multigene panel test looks for specific inherited or somatic mutations in named genes such as BRCA1, BRCA2, PALB2 and ATM. HRD testing is done on tumour tissue and measures whether the tumour as a whole shows genomic signs of homologous recombination failure — a pattern of accumulated damage — regardless of which gene caused it. Some PARP inhibitor approvals are based on HRD tumour testing rather than a specific gene mutation. Both types of result can be relevant, and your oncologist may order one or both depending on your cancer type and the treatment being considered.
Should my family members be tested if I have a PALB2 or ATM mutation?
Yes, this is worth discussing. Both PALB2 and ATM are inherited in an autosomal dominant pattern, meaning each first-degree relative — parents, siblings, children — has roughly a one-in-two chance of carrying the same mutation. A clinical geneticist or genetic counsellor can explain what the finding means for your relatives and guide the process of cascade testing. This conversation is separate from your own treatment planning but equally important for the family as a whole.
Can I access a PARP inhibitor privately in India if my gene is not on the approved list?
Some drugs can be accessed off-label, but this decision requires careful clinical judgement. Accepting real side-effect risk from a treatment with uncertain benefit for your mutation is a significant trade-off. A more appropriate route is to ask your oncologist whether you are eligible for a clinical trial, which gives supervised access to the drug while contributing to the evidence base that will help future patients. Your oncologist can search ClinicalTrials.gov and the Clinical Trials Registry of India for open studies that include your mutation and cancer type.